Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

ate-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition.  Afatinib is an investigational orally-administered irreversible inhibitor of the ErbB family of receptor tyrosine kinases, which is currently in phase III clinical development in advanced NSCLC, head and neck cancer, and breast cancer.  Boehringer Ingelheim recently submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of afatinib as a treatment for patients with EGFR (ErbB1) mutation-positive NSCLC.  The company is working on applications for afatinib in a number of countries, including the United States.  Nintedanib (BIBF 1120) is an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis and is currently in Phase III clinical development in NSCLC and ovarian cancer.  Volasertib is an investigational inhibitor of polo-like kinase that is currently being investigated in early phase trials.  Boehringer Ingelheim's oncology pipeline continues to evolve and demonstrates the company's continued commitment to the disease area.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110.  Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one o
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... inVentiv Health, Inc., offering best-in-class clinical, commercial ... today that it has been selected by the ... operations support, as well as recruiting and sales ... for Type 2 diabetes. inVentiv ...
... Amex: CUR ) announced that the ongoing Phase ... amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease) was featured ... (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The trial was ... About Neuralstem ...
... 2011 VIVUS, Inc. (NASDAQ: VVUS ) ... 3 long-term safety and efficacy study of the investigational ... was presented over the weekend at the 2011 Sexual ... Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology ...
Cached Biology Technology:inVentiv Health Selected to Provide Sales Operations Support for Santarus 2inVentiv Health Selected to Provide Sales Operations Support for Santarus 3inVentiv Health Selected to Provide Sales Operations Support for Santarus 4Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 315-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 4
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... A once-a-day, short-term treatment with a drug compound substantially ... symptoms, say researchers at the Stanford University School of ... gains lasted for months after the treatment was discontinued. ... test whether the compound has a similar effect in ...
... tough job. Yet, our bones undergo remodeling every day of ... new bone can form. In diseases such as osteoporosis, an ... loss. New research at the Weizmann Institute of Science, which ... in unprecedented detail how the roving cells whose job is ...
... slowly ebbing due to degenerative diseases of the eye, the ... , In a study in rats, neural progenitor cells derived ... the vision of animals with degenerative eye disease similar to ... appears today (March 28) in the journal Public Library of ...
Cached Biology News:Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 2Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 3Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows 4Ring-around-the-cell 2Stem cell therapy shows promise for rescuing deteriorating vision 2Stem cell therapy shows promise for rescuing deteriorating vision 3
Recombinant Feline IL-2, CF...
Recombinant Rat Leptin, CF...
delta-like 1 homolog (Drosophila)...
... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
Biology Products: